San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived...
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived...
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived...
Name change reflects Company’s evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived...
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing proprietary...
Renewed team and capital focused on advancing lead compound for glaucoma into human studies
San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules...